| pubmed-article:16115132 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16115132 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16115132 | lifeskim:mentions | umls-concept:C0005961 | lld:lifeskim |
| pubmed-article:16115132 | lifeskim:mentions | umls-concept:C0002874 | lld:lifeskim |
| pubmed-article:16115132 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:16115132 | lifeskim:mentions | umls-concept:C0009647 | lld:lifeskim |
| pubmed-article:16115132 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:16115132 | lifeskim:mentions | umls-concept:C0003442 | lld:lifeskim |
| pubmed-article:16115132 | lifeskim:mentions | umls-concept:C1517942 | lld:lifeskim |
| pubmed-article:16115132 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
| pubmed-article:16115132 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:16115132 | pubmed:dateCreated | 2005-8-23 | lld:pubmed |
| pubmed-article:16115132 | pubmed:abstractText | A total of 81 severe aplastic anaemia patients, aged 2-63 years, received human leucocyte antigen-matched related marrow grafts after cyclophosphamide + antithymocyte globulin followed by postgrafting methotrexate + cyclosporin. Median follow-up was 9.2 years. Ninety-six per cent of patients had sustained engraftment, 24% developed acute graft-versus-host disease (GVHD), grade II in all but two patients, and 26% developed chronic GVHD; all surviving patients eventually responded to immunosuppressive therapy. Six patients developed cancer: one fatal lymphoma and five carcinomas (all five patients are now free of cancer). Survival was 88%. The regimen appeared well tolerated and effective in heavily pretreated patients with aplastic anaemia. | lld:pubmed |
| pubmed-article:16115132 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16115132 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16115132 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16115132 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16115132 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16115132 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16115132 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16115132 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16115132 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16115132 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16115132 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16115132 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16115132 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:16115132 | pubmed:author | pubmed-author:StorbRainerR | lld:pubmed |
| pubmed-article:16115132 | pubmed:author | pubmed-author:MartinPaul... | lld:pubmed |
| pubmed-article:16115132 | pubmed:author | pubmed-author:SandersJean... | lld:pubmed |
| pubmed-article:16115132 | pubmed:author | pubmed-author:FlowersMary... | lld:pubmed |
| pubmed-article:16115132 | pubmed:author | pubmed-author:DeegH... | lld:pubmed |
| pubmed-article:16115132 | pubmed:author | pubmed-author:LeisenringWen... | lld:pubmed |
| pubmed-article:16115132 | pubmed:author | pubmed-author:ChaunceyThoma... | lld:pubmed |
| pubmed-article:16115132 | pubmed:author | pubmed-author:KahlChristoph... | lld:pubmed |
| pubmed-article:16115132 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16115132 | pubmed:volume | 130 | lld:pubmed |
| pubmed-article:16115132 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16115132 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16115132 | pubmed:pagination | 747-51 | lld:pubmed |
| pubmed-article:16115132 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:meshHeading | pubmed-meshheading:16115132... | lld:pubmed |
| pubmed-article:16115132 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16115132 | pubmed:articleTitle | Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. | lld:pubmed |
| pubmed-article:16115132 | pubmed:affiliation | Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. | lld:pubmed |
| pubmed-article:16115132 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16115132 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:16115132 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16115132 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16115132 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16115132 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16115132 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16115132 | lld:pubmed |
